Ampio Pharmaceuticals Inc (AMPE)
0.33
+0.08
(+31.47%)
USD |
OTCM |
May 01, 15:59
Ampio Pharmaceuticals Research and Development Expense (Quarterly): 1.242M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.242M |
| September 30, 2023 | 0.329M |
| June 30, 2023 | 0.344M |
| March 31, 2023 | 0.524M |
| December 31, 2022 | 0.739M |
| September 30, 2022 | 2.747M |
| June 30, 2022 | 1.743M |
| March 31, 2022 | 3.687M |
| December 31, 2021 | 4.737M |
| September 30, 2021 | 2.594M |
| June 30, 2021 | 2.273M |
| March 31, 2021 | 2.296M |
| December 31, 2020 | 2.145M |
| September 30, 2020 | 1.655M |
| June 30, 2020 | 1.118M |
| March 31, 2020 | 4.254M |
| December 31, 2019 | 5.493M |
| September 30, 2019 | 3.428M |
| June 30, 2019 | 2.136M |
| March 31, 2019 | 1.564M |
| December 31, 2018 | 1.486M |
| September 30, 2018 | 1.184M |
| June 30, 2018 | 2.115M |
| March 31, 2018 | 2.044M |
| December 31, 2017 | 3.438M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.993M |
| June 30, 2017 | 3.350M |
| March 31, 2017 | 1.640M |
| December 31, 2016 | 1.642M |
| September 30, 2016 | 1.788M |
| June 30, 2016 | 2.805M |
| March 31, 2016 | 4.312M |
| December 31, 2015 | 4.424M |
| September 30, 2015 | 3.654M |
| June 30, 2015 | 3.113M |
| March 31, 2015 | 3.920M |
| December 31, 2014 | 2.784M |
| September 30, 2014 | 6.220M |
| June 30, 2014 | 5.634M |
| March 31, 2014 | 7.829M |
| December 31, 2013 | 5.115M |
| September 30, 2013 | 4.420M |
| June 30, 2013 | 4.737M |
| March 31, 2013 | 2.787M |
| December 31, 2012 | 0.8846M |
| September 30, 2012 | 2.135M |
| June 30, 2012 | 1.552M |
| March 31, 2012 | 1.473M |
| December 31, 2011 | 3.602M |
| September 30, 2011 | 1.404M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.329M
Minimum
Sep 2023
5.493M
Maximum
Dec 2019
2.289M
Average
2.145M
Median
Dec 2020
Research and Development Expense (Quarterly) Benchmarks
| NeuBase Therapeutics Inc | 0.3876M |
| Tivic Health Systems Inc | 0.36M |
| Oragenics Inc | 11.04M |
| Actinium Pharmaceuticals Inc | 8.118M |
| MAIA Biotechnology Inc | 3.717M |